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Monocyte and macrophage markers are among the most
highly overexpressed genes in cpk mouse kidneys with
severely progressive renal cystic disease. We show here
that one of these markers, CD14, is abnormally transcribed,
activated and shed in cystic kidneys. However, these
abnormalities were not associated with an increased number
of interstitial CD14-positive mononuclear cells. Instead, we
found that most non-cystic and cystic renal tubular epithelia
were CD14-positive; even distal nephron-derived principal
cells. Cd14 was significantly overexpressed in the kidneys
of 5-day-old cpk mice and further increased as the disease
progressed. In the cpk model with variable rates of cystic
kidney enlargement (due to an intercross of two distinct
genetic backgrounds), Cd14 expression positively correlated
with kidney volume, exceeding the correlation with MCP-1,
an established marker of autosomal-dominant polycystic
kidney disease (ADPKD). In 16 patients with ADPKD, the
baseline urinary CD14 level showed some tendency to
correlate with the 2-year change in total kidney volume;
however, the tendency was not statistically significant.
But the association was significant when the analysis was
confined to males. Clearly more studies need to be done
to evaluate the utility of CD14 as a marker for outcomes
in ADPKD.
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Polycystic kidney disease (PKD) is a major cause of end-stage
renal disease in children and adults.1 It affects over 600,000
people in the United States and 12.5 million world-wide.
Autosomal-dominant PKD (ADPKD; MIM 173900; 173910)
occurs in 1:400–1:1000 individuals. ADPKD is caused by
mutations in one of two genes, PKD1 or PKD2.2–5 Autosomal
recessive PKD (RPKD; MIM 263200) occurs in 1:20,000 live
births and is caused by defects in a single gene, PKHD1.6,7
Innate immune system abnormalities are a dominant
feature of both ADPKD and RPKD. In ADPKD, renal
parenchyma is infiltrated by mononuclear cells,8 perhaps in
response to accelerated production of monocyte chemotactic
protein 1 (MCP-1).9,10 We have observed monocytic
infiltrates also in RPKD.11 Until recently, these PKD-related
innate immune response abnormalities were thought to be
associated with advanced stages of the disease progression
and were not considered to have a substantial impact on
clinical outcomes. Discovery of abnormal urinary excretion
of MCP-1 in early disease stages in ADPKD patients and an
animal model9,10 changed this paradigm by demonstrating
that innate immunity is altered early in the disease
pathogenesis. In addition, several recent lines of evidence
suggest that immune responses directly promote cystogen-
esis, at least in animal models.12–15
To further elucidate the role of innate immune cells in
PKD pathogenesis, we studied cpk mouse model of RPKD
with variable rates of cystic kidney disease progression
because of the admixture of two genetic backgrounds.16
In this model, we have identified 60 monocyte/macrophage-
associated markers that are overexpressed in kidneys from cpk
mice with severely vs mildly progressive cystic kidney
disease.11 An overexpression of macrophage markers associated
with a wound healing- and fibrosis-promoting alternative
activation pathway suggests that a PKD-associated mononuclear
cell-like response contributes to the pathogenesis of interstitial
fibrosis, a typical feature of advanced PKD. This hypothesis is
consistent with the belief that interstitial inflammation is the
leading cause of renal dysfunction in PKD.17,18
The substantial magnitude of PKD-associated innate
immune abnormalities was recently revealed by genome-
wide transcription profiling studies. For example, in the
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cpk mouse model, genes-encoding markers of macrophages,
together with additional innate immune factors, represent
the most highly overexpressed group of genes in a severely
progressive cystic kidney disease.11 Similar abnormalities
were revealed by genome-wide expression profiling study of
Han:SPRD-Cy rat kidneys that were harvested months before
measurable changes in renal function.19 The specific role
of immunity in PKD pathogenesis is further suggested by
cystogenesis-inhibiting effects of several immunosuppressive
drugs (for example, glucocorticoids, mycophenolate mofetil,
and mTOR, and TNFa inhibitors).12–15
In this study, we characterize PKD-associated expression
of CD14, a widely used marker of mature monocytes and
macrophages and one of the most highly overexpressed genes
in cpk mice with severely vs mildly progressive cystic renal
disease.11 CD14 is a pattern recognition receptor20 that
operates in conjunction with Toll-like family of receptors
(summarized in Kim et al.21) as a high affinity homing
receptor for lipopolysacharide (LPS) having a key role in
LPS-induced immune response activation. However, it may
also bind apoptotic cells and fungi. CD14 is highly expressed
in mature monocytes and macrophages and to a lesser degree
in a wide range of non-myeloid cell types including proximal
tubular cells (summarized in Morrissey22). It is also found in
milk, cerebrospinal fluid, serum, and urine.
CD14 was originally described in mononuclear cells as a
55 kDa protein anchored to cell surface by linkage to
glycosylphosphatidylinositol (GPI; mCD14).23 However, after
activation of these cells (for example, by LPS), soluble CD14
can be released in large quantities either by protease-
dependent shedding (as approximately a 48 kDa fragment)
or by protease-independent release of a larger (approximately
55 kDa) protein that escaped posttranslational modifications
(including attachment of the GPI anchor)24 (see schema;
Figure 1).
In this study, we present a comprehensive analysis of
CD14 expression in kidneys of 10-day-old cpk mice and
its relationship to rates of renal cystic disease progression.
We also characterize postnatal Cd14 gene expression in cpk
and wild-type mice. Finally, we examine CD14 protein
content in mouse and human cystic kidneys and explore
CD14’s potential as a putative marker for predicting rates of
change in kidney volume in ADPKD.
RESULTS
Cd14 expression correlates with rates of renal cystic
disease progression in cpk mice
We examined Cd14 gene expression profiles of cystic kidneys
from 10-day-old mice selected among an F2 cohort of
affected cpk mice (n¼ 461) that were generated in an
(C57BL/6J-cpk/þ  CAST)F1 intercross.16 This intercross
represents a model that provides variable rates of cystic
kidney disease progression. Previously, we generated genome-
wide renal expression analyses of the seven most mildly
affected and seven most severely affected mice from this
cross.11 In this study, we examined renal Cd14 expression in
the seven most mildly affected mice, eight mice selected
evenly across phenotypic spectrum of renal cystic disease
severity (defined by kidney length, weight, and volume),16
and an additional seven unaffected mice. Cd14 expression in
these kidneys determined with quantitative TaqMan assays
correlated strongly with kidney volumes ((r¼ 0.94,
Po0.001); Figure 2a), resembling closely our initial Affyme-
trix 430 2.0 array-based Cd14 expression analyses (data not
shown). However, there was a gender difference in these
correlations (r¼ 0.95 and Po0.001 for male, r¼ 0.74 and
P¼ 0.02 for female mice).
Cd14 expression was more strongly correlated with kidney
volume than expression of Ccl2, which showed moderately
strong correlation with kidney volume (r¼ 0.79, Po0.001;
Figure 2b). Ccl2 encodes MCP-1, the only surrogate marker
of PKD progression extensively validated in ADPKD patients
and an animal PKD model.9,10 Similar to the Cd14 expression
data, these analyses closely resembled Affymetrix 430 2.0
array data generated during our initial evaluation of Ccl2
expression (data not shown).
Renal Cd14 expression in cpk mice is abnormally increased
in early postnatal period
The above renal Cd14 gene expression data reflect a snapshot
at 10 days of age across a spectrum of renal cystic phenotypes
resulting from variable rates of disease progression.
In the cpk model, these variable rates were induced by
different admixtures of two distinct genetic backgrounds
in the (C57BL/6J-cpk/þ  CAST)F1 intercross. To better
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Figure 1 | Schema of CD14-mediated immune response
activation and CD14 shedding. CD14 is a high affinity
lipopolysacharide (LPS) receptor that, in conjunction with Toll-like
family receptors (for example, TLR4), activates LPS-induced
immune responses. CD14 is anchored to cell surfaces by a linkage
to glycosylphosphatidylinositol (GPI). However, activated cells
may release CD14 by proteinase-dependent (48 kDa) or
proteinase-independent shedding (55 kDa protein).
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characterize the temporal course of Cd14 expression during
cystic disease progression, we examined its expression in 0-,
5-, 10-, 15-, 20- and 25-day-old (P0-P25) kidneys from cpk
and wild-type mice with an exclusive C57BL/6J genetic
background. Consistent with previous observations of
developmental regulation of CD14 expression in humans,25
these analyses revealed that renal Cd14 expression in wild-
type mice is developmentally regulated. Specifically, in the
wild-type kidneys Cd14 expression increased over 4-fold
during the first 3 weeks of life (Figure 2c). In cpk kidneys,
increase in Cd14 expression was even more accelerated,
leading to a significant (1.4-fold; Po0.05) difference between
cpk and wild-type kidneys by 5 days of age (Figure 2c). The
Cd14 overexpression in cpk kidneys further increased with
progressing age until P25, the last scored timepoint before
presumable death due to uremia around 4 weeks of age.
In contrast, overexpression of Ccl2, an MCP-1-encoding
gene, in cpk vs wild-type kidneys was less prominent and
more variable (Figure 2d).
CD14þ mononuclear cell content is not significantly
increased in cpk kidneys
Since monocytes and macrophages are major sources of
CD14, we examined the numbers of these cells in 10-day-old
cpk kidneys. Staining with several anti-CD14 antibodies
identified interstitial monocyte- and macrophage-like cells in
both cystic cpk and wild-type kidneys. In contrast to Cd14
overexpression in cpk kidneys, the number of strongly
CD14-positive interstitial cells per mm2 tissue (excluding
cyst and tubular lumina) was not significantly increased in
the cortex of cpk vs wild-type kidneys, and it was significantly
decreased in the medulla of cpk vs wild-type kidneys
(Figure 3a and b). These data indicate that increased levels
of Cd14 gene expression in cpk kidneys cannot be attributed
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Figure 2 |Correlation between Cd14 expression and cystic kidney disease severity in cpk mice. (a) Shows a strong correlation of Cd14
expression with kidney volumes in 10-day-old mice generated in (C57BL/6J-cpk x CAST/Ei)F1 intercrosses (r¼ 0.94, Po0.001). Black symbols
designate affected cpk mice, white symbols correspond to unaffected littermates, diamonds represent males and circles females. This panel
also demonstrates that Cd14 expression is significantly increased even in the most mildly affected cpk kidneys vs unaffected littermate
kidneys (Po0.05; bracketed data points). (b) Demonstrates the outcomes of similar analyses for Ccl2, a gene encoding a surrogate polycystic
kidney disease progression marker MCP-1. The correlation of Ccl2 expression and kidney volumes was moderately strong (r¼ 0.79,
Po0.001). However, the difference in Ccl2 expression levels between unaffected and mildly affected cpk kidneys was not significant. (c and
d) Show relative renal Cd14 and Ccl2 expression in early postnatal period. Black diamonds represent mean gene expression values for
specific time-points in affected cpk mice, white circles correspond to mean gene expression in unaffected littermates, bars indicate 1 s.d.
Asterisks mark statistically significant differences between data for kidneys from cpk mice and unaffected littermates (*Po0.05, **Po0.01,
***Po0.001).
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to an increased number of interstitial CD14-positive
mononuclear cells.
CD14 can be produced by cystic and non-cystic renal
tubular epithelia
In addition to monocytes and macrophages, CD14 can be
expressed by non-myeloid cells such as endothelial cells
and proximal tubular cells (summarized in Morissey22). To
determine whether these non-myeloid cells participate
in CD14-associated innate immune responses in PKD, we
compared patterns of antigenic CD14 expression/deposition
in kidneys from 10-day-old cpk mice vs wild-type littermates.
Similar to previous studies showing that proximal tubular
cells can produce CD14,22 our immunohistochemical ana-
lyses revealed varying intensities of CD14 protein staining
that were detected in non-cystic tubular epithelia of wild-
type and cpk kidneys (Figure 3a). In addition, cell membrane
and cystoplasm of epithelial cell lining of most cpk cysts also
stained with anti-CD14 antibody and the intensity of this
staining was stronger in kidneys with more advanced disease
(P15 and P20; Supplementary Figure S1). This CD14
production by principal cells of collecting duct that form
epithelial cell lining of most RPKD cysts has not been
previously described. The capacity of these cyst-forming
epithelial cells to produce CD14 protein is further supported
by the presence of both Cd14 mRNA and CD14 protein in
principal cells of a SV40-immortalized internal medullary
collecting duct cell line mIMCD-K2 (Figure 3c).
cpk kidneys contain increased levels of shedded CD14
fragments
To explore whether the PKD-associated increase in Cd14 gene
expression translates also to an increased generation and/or
processing of the CD14 protein, we examined kidneys of
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Figure 3 |CD14-positive mononuclear cell content is not significantly increased in cpk kidneys. (a) Shows a representative micrograph
of an anti-CD14 antibody stained section of wild type (þ /þ ) 10-day-old kidney showing few strongly positive CD14 cells in interstitium
(presumably mature monocytes and macrophages; marked by arrows) and weaker staining in tubular cells. In 10-day-old cpk kidneys there
is a similar weak staining of both non-cystic and cystic renal epithelial cells as well as strong staining of CD14-positive interstitial cells.
(b) Shows that the content of strongly stained CD14-positive mononuclear cells in interstitium is not significantly increased in cpk kidneys.
(c) Demonstrates the CD14 producing capacity of principal cells from inner medullary collecting duct cell line mIMCD-K2 (IMCD); reverse
transcriptase PCR (RT-PCR) with Cd14-derived primers produced a cDNA-specific 258 bp product (asterisk), anti-CD14 immunoblotting of
IMCD lysates showed a 55 kDa protein that is present in non-activated CD14-producing cells.
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10-day-old cpk and wild-type mice by immunoblotting with
anti-CD14 antibodies. In contrast to the gene expression
profiling data, immunoblotting analyses showed decreased
levels of total CD14 protein in cpk kidneys (Figure 4).
However, the content of the 48 kDa CD14 variant that is
generated by proteolytic shedding from immunologically
activated or injured cells26 was significantly increased in the
cpk vs wild-type kidneys (Figure 4).
CD14 processing is abnormal in human RPKD kidneys
Informed by CD14 expression and processing abnormalities
in the cpk mouse, we also characterized CD14 expression
in human PKD kidneys. First, we tested the expression of
antigenic CD14 in kidneys from B21-week-old control and
RPKD fetuses. Similar to the 10-day-old cpk kidneys, the
RPKD kidneys contained strongly CD14-positive interstitial
cells. However, cytoplasmic staining of human fetal cystic and
non-cystic renal tubular cells was more intense when
compared with CD14-positive interstitial cells (Figure 5a,
left panel). Immunoblotting analyses of RPKD kidneys vs
control fetal kidneys (Figure 5b, left panel) closely parallel the
lower CD14 content in cystic cpk vs wild-type kidneys.
Similarly, immunoprecipitated urine from RPKD patients
with mild to moderately advanced disease (CrCl 39–123 ml/
min) showed the presence of both soluble CD14 forms
(48 and 55 kDa, Figure 5c).
CD14 is abnormally processed and excreted in ADPKD
Consistent with previous reports of interstitial mononuclear
cell infiltrates in ADPKD kidneys,8 we observed the presence
of CD14þ mononuclear cells in interstitium of end-stage
ADPKD kidneys (Figure 5a, right panel). In contrast to
RPKD, CD14 staining of tubular epithelia in ADPKD was
more sporadic and epithelial lining of only a subset of renal
cysts was formed by CD14-positive cells.
Immunoblotting of human end-stage ADPKD kidneys
resembled RPKD data with low CD14 content in cystic vs
normal control kidneys (Figure 5b, right panel). These data
suggested that abnormal CD14 shedding in PKD kidneys is
followed by its washout to urine or plasma. Consistent with
this hypothesis, immunoprecipitated urine from ADPKD
patients with mild to moderately advanced disease (CrCl
49–129 ml/min) showed the presence of both soluble
CD14 forms (48 and 55 kDa, Figure 5c). The CD14 was
present also in cyst fluid in approximately 10 to 100-fold
higher concentrations than urinary CD14 levels (determined
by ELISA).
CD14, a candidate predictor of ADPKD progression rates
Because Cd14 gene expression in cpk kidneys correlated
strongly with rates of renal cystic disease progression
(Figure 2), we speculated that urinary levels of shed CD14
may also correlate with rates of disease progression in
ADPKD. Quantitative ELISA-based analyses of CD14 levels in
a small group of ADPKD patients (n¼ 16; nine Caucasian
male and seven female patients; average iothalamate
glomerular filtration rate (GFR) 86 ml/min) support this
hypothesis. Specifically, baseline urinary CD14 levels corre-
lated with a 2-year rate of PKD progression determined by a
relative change (second year follow up to baseline ratio) in
total kidney volume (TKV; overall r¼ 0.43, P¼ 0.09; for male
patients only r¼ 0.74, P¼ 0.02; Figure 6) suggesting
potential utility of urinary CD14 levels for predicting
ADPKD outcomes. Adjustment for urinary creatinine
decreased these correlations (overall r¼ 0.26, P40.20, for
male patients r¼ 0.55, P¼ 0.12). In comparison, the
correlation of the relative TKV change with the initial
iothalamate GFR was not significant (r¼ (0.22), P40.20)
in the studied group of patients.
In contrast to CD14, the correlation of urinary MCP-1
levels with the rate of ADPKD progression was weak and did
not reach statistical significance (overall r¼ 0.19, for male
patients only r¼ 0.21, both P40.20). Similarly, weaker
correlations were obtained between Ccl2 (vs Cd14) expression
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Figure 4 |CD14-producing cells are abnormally activated in cpk kidneys. A representative immunoblot of kidney lysates from
10-day-old cpk (cpk/cpk) and wild type (þ /þ ) mice demonstrates that while the total CD14 content is reduced in the cpk kidneys,
these kidneys contain increased amounts of the 48 kDa CD14 fragment that is generated by shedding of membrane-bound CD14 from
activated cells.
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and rates of cystic kidney disease progression in cpk kidneys
(Figure 2).
As serum represents a potential source of urinary CD14 or,
alternatively, renal CD14 may leak to systemic circulation, we
also evaluated serum CD14 levels in this ADPKD cohort. The
overall correlation of logarithmically adjusted serum CD14
values with a 2-year rate of PKD progression determined by a
relative TKV change (r¼ 0.43, P¼ 0.09, n¼ 17) resembled
correlations of urine CD14 values with TKV change.
However, these correlations did not appear to vary by gender
(r¼ 0.44 male patients, r¼ 0.42 female patients). Correla-
tions between unadjusted as well as adjusted CD14 urinary
and serum values were weak and not significant (ro0.25,
P40.20, n¼ 28). Together, these data point to urine and
serum CD14 as potentially independent candidate markers of
PKD progression. However, these observations require
validation on a larger well-characterized ADPKD cohort.
DISCUSSION
We have recently demonstrated that genes encoding CD14
and other innate immune system factors are most highly
overexpressed in age-matched cpk mice with severe vs mild
rates of renal cystic disease progression.11 This study
confirmed and extended this initial observation.
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Figure 5 |CD14 expression in human RPKD and ADPKD. (a) Shows representative micrographs of anti-CD14 antibody stained sections of
fetal recessive PKD (RPKD) and adult Autosomal-dominant PKD (ADPKD) kidneys. CD14-positive interstitial cells (presumed mature
monocytes and macrophages) are present in both RPKD and ADPKD kidneys. Cystic as well as non-cystic epithelial cells were CD14-positive,
resembling staining of cpk mouse kidneys. However, staining of renal tubular cells in fetal RPKD kidneys was comparable in strength to
CD14-positive interstitial cells. CD14 content in cell membrane and cytoplasm closely resembled known CD14 distribution in macrophages.
Although not frequent, a similar pattern of CD14 expression was observed also in some non-cystic tubular cells (arrow) and epithelial cell
lining in end-stage ADPKD kidneys. The CD14-like staining pattern was absent in corresponding mouse and human tissues stained with pre-
immune sera and/or control antibodies. (b) Shows that similar to cpk mouse kidneys, CD14 content is decreased in lysates from RPKD and
ADPKD kidneys. A possible explanation for the polycystic kidney disease (PKD)-associated reduction in renal CD14 content is its shedding by
activated cells. After their activation, these cells shed a GPI-anchor-attached CD14 from cell membrane in the form of its 48 kDa CD14
fragment as well as yet unprocessed 55 kDa CD14 protein that are both present in urine from RPKD and ADPKD patients (c). Column
numbers (b and c) designate sample assignment of unique individuals.
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Particularly intriguing is the finding of Cd14 overexpres-
sion in 5-day-old cpk (vs unaffected) kidneys (Figure 2c) that
occurred in very early stages of the disease. Similarity
between this early Cd14 expression pattern and that of
Ccl2, a gene encoding the potent chemotactic factor MCP-1,
which recruits mononuclear cells to sites of injury and
inflammation (Figure 2d), suggests that the observed Cd14
expression abnormalities in cystic kidneys reflect accelerated
mononuclear cell recruitment because of increased MCP-1
expression. However, we did not observe significantly higher
numbers of CD14þ mononuclear cells in cystic cpk kidneys.
Instead, our data suggest that alternative CD14-producing
(for example, epithelial) cells are the major source of early
CD14 expression abnormalities in cystic kidneys. As renal
epithelial cells from proximal tubules22 and, as our data
suggest, also from distal nephron segments, express CD14, it
is likely that both CD14 and MCP-1 expression abnormalities
in cpk kidneys reflect an independent response of renal
tubular cells to the cystic disease-related injury and/or
incomplete or aberrant tubular cell differentiation. The
absence of early overexpression of genes encoding other
macrophage markers (for example, CD68 or CD163) in
5-day-old cpk kidneys (data not shown) further supports this
hypothesis. Interestingly, the Cd14 and Ccl2 expression
abnormalities preceded significant changes in expression of
Lcn2 (data not shown), a gene encoding an acute renal
tubular injury marker neutrophil gelatinase-associated lipo-
calin (summarized by Devarajan27). Together, these observa-
tions suggest that innate immune abnormalities represent
one of the earliest responses exerted by renal tubular cells
affected by a cystogenesis-promoting gene defect. It is
conceivable that these innate immune responses alter sus-
ceptibility of renal tubular cells to cystogenic stimuli. A
reduction of cystogenesis by inhibition of TNFa,15 a down-
stream component of the CD14/TLR4-signaling pathway
(summarized in Togbe et al.28), is consistent with this
hypothesis. This paradigm also suggests that immunosup-
pressive rather than antiproliferative effects of sirolimus and
mycophenolate mofetil are responsible for cystogenesis
inhibiting effects of these drugs.13,14
Triggers of CD14 overexpression in PKD remain to be
determined. We speculate that in RPKD, where the cystically
dilated renal tubules do not form cysts that are isolated from
the nephron, CD14 may be a marker of renal tubular cells’
response to injury caused directly by the primary cystogenic
defect. Alternatively, CD14 expression may reflect responses
to renal epithelia injury caused by secondary or non-renal
effects of cystogenic mutations (for example, hypertension).
As several recent studies suggest that injury and/or renal
tubular responses to injury are critical in cystogenesis
(summarized in Verdeguer et al.29 and Li et al.15), it is
possible that CD14 levels may be associated with cystogenic
potential or ‘nascent cyst formation’. We hypothesize that
similar concepts can be applied to ADPKD, but with additional
levels of complexity due to different responses in cells that
sustained the ‘second cystogenic hit’ (reviewed by Pei30) and
haploinsufficient ADPKD cells that may form microcysts
after an injury.31 Indeed, CD14 expression, processing and
shedding may also reflect other effects of PKD on renal
epithelia such as biomechanical effects of cyst expansion.
The specific consequences of increased renal CD14
expression, activation, and shedding in PKD remain
unknown. It is possible that intratubular CD14, as a potent
stimulator of TNFa secretion,32 promotes cystogenesis
primarily by activating the cystogenic TNFa pathway.
However, CD14 effects are likely complex. As the shed
CD14 is a known mediator of renal endotoxin-induced
tubulointerstitial injury,33 an endotoxin or other factors that
bind to this pattern recognition receptor20 may also lead to
immune activation and/or injury of renal tubular cells in a
complex process that resembles the activation of professional
immune cells. We speculate that this ‘immune activation’ of
renal epithelial cells changes their susceptibility to cystogenic
stimuli across developmental stages and that this activation
can be triggered by numerous factors that lead to substantial
renal distress. For example, it is possible that CD14 activation
accelerates cystogenesis before response to PKD defects is
downregulated at P12-14 (for example, in an inducible
orthologous Pkd1 model34). However, immune stimuli may
promote cystogenesis also in mature kidneys with increased
susceptibility to PKD defects. Such cystogenesis-promoting
effects were observed, for example, after renal ischemia-
reperfusion injury,35 which similarly to our PKD-related
observations, leads to CD14 overexpression in renal tubular
cells without increasing the number of infiltrating mono-
nuclear cells.22
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On a molecular level, as a major ligand for Toll-like
receptor 4 (TLR4) CD14 may directly transactivate cysto-
genic pathways (reviewed in Torres and Harris36) modulated
by TLR4 signaling, for example, the Wnt pathway37 or Rho
and PI3K pathways (reviewed by Ruse and Knaus38). Altered
TLR4 signaling may also affect the AP-1-signaling pathway
(reviewed in Hu et al.39) that has been linked to cystogenesis
in PKD1 defects.40 As TLR4 is expressed across the nephron
including proximal tubules and collecting ducts (summarized
in Good et al.41), it is possible that renal tubular cell-derived
CD14 may activate TLR4 locally in a paracrine (perhaps even
autocrine) fashion. Alternatively, filtered or exosomal CD1442
(that may be in part proximal nephron-derived) may exert
more distal effects, for example, by activating TLR4 on
principal cells of collecting duct, a major cyst-forming
cell type.
Additional evidence supporting the role of CD14/TLR4
signaling in PKD pathogenesis stems from the fact that the
Tlr4 gene is a candidate modifier of cystic kidney disease.
It fulfills major modifier gene criteria established by the
Complex Trait Consortium:43 (1) it maps to 33 cM on
chromosome 4 under the main quantitative trait locus for
renal cystic and billiary phenotypes in cpk mice;16 (2) its gene
expression (data not shown) as well as the expression of its
major ligand CD14 (Figure 2) correlates with the rates of
cystic disease severity in cpk mice; (3) the Tlr4 gene has
C57BL/6J and CAST/Ei strain-specific haplotypes with
several functionally relevant variants; (4) it is predominantly
expressed in the newborn period (according to EST Profile
Viewer; http://www.ncbi.nlm.nih.gov/unigene) a time period
most relevant to the studied modifier gene effect;16 (5) it is
expressed by both renal tubular and biliary epithelial
cells;44,45 and finally (6) TLR4 is a major regulator of
cystogenic factor TNFa.15 However, Tlr4’s modifier gene
effects have to be validated by functional studies.
In this study we observed strong correlations between
Cd14 expression and 10-day cpk kidney volumes that reflect
rates of cystic disease progression in this model. To determine
whether similar association between CD14 expression and
the rate of disease progression exist also in ADPKD,
we evaluated correlations between rates of cystogenesis
(expressed as relative change in TKV over a 2-year period)
in a small group (n¼ 16) of well-characterized patients
selected from participants of the Emory ADPKD Cohort
Study. Similar to studies that showed significant associations
of unadjusted urine neutrophil gelatinase-associated lipocalin
levels with high cyst growth rate in ADPKD46 and faster
doubling of serum creatinine in other chronic kidney
disorders,47 our analyses presented in this article revealed
moderately strong correlations between unadjusted urinary
CD14 levels and the rate of ADPKD (TKV) progression.
However, our analyses are limited by small sample size that
did not allow the evaluation of multiple covariate effects.
Therefore, validation of these data has to be performed on a
larger well-characterized cohort of ADPKD patients. Ideally,
such analyses should also determine whether random or
timed urinary CD14 excretion can be used as a short-term
marker of disease activity that cannot be revealed by imaging
studies because of too short follow-up intervals. The use of
CD14 as such a marker may allow a more accurate titration
of supportive or future PKD-specific therapies and may
complement additional emerging markers of PKD progres-
sion, such as renal volume48 or specific small peptides
detected by capillary electrophoresis coupled to mass
spectrometry (CE-MS).49 CD14 may be especially useful as
a marker if future therapies alter the CD14/TLR4-signaling
pathway. In addition, it remains to be determined whether
functional polymorphisms within CD14 gene (for example,
its promoter)50 influence specific PKD outcomes.
Finally, both Cd14 mRNA expression in the studied mouse
kidneys and urinary CD14 levels in ADPKD patients
correlated better with rate of kidney volume change in male
than in female patients. We speculate that these gender
differences reflect distinct female-specific innate immune
responses that include regulation of CD14 levels.51 In
addition, CD14 excretion in urine from female patients
may be influenced by menstrual cycle similarly as excretion of
other factors that activate components of CD14/TLR4
signaling (for example, IL-152).
In summary, we have performed the first comprehensive
analysis characterizing CD14 expression in PKD. In the cpk
mouse, a model of recessive PKD, we determined that
abnormalities in Cd14 gene expression represent an early
postnatal event. In addition, in a model that provides variable
rates of cystic kidney disease progression, Cd14 expression
positively and strongly correlated with the rate of cystogen-
esis reflected by kidney volumes of 10-day-old cpk kidneys.
We showed that similar to renal ischemia-reperfusion injury,
CD14 expression abnormalities in cpk kidneys cannot be
attributed to increased numbers of CD14þ monocytes or
macrophages, but rather they reflect increased immunologi-
cal activity of renal tubular cells. Results of CD14 studies in
human kidneys from patients with RPKD closely resembled
observations in cpk kidneys, in particular with respect to
CD14 immunolocalization and renal CD14 content. Inter-
estingly, we observed CD14 expression abnormalities also in
ADPKD kidneys and our initial analyses indicate that CD14
is a candidate predictor of ADPKD progression.
MATERIALS AND METHODS
Mice
Details of the generation of the (C57BL/6J-cpk/þ  CAST)F1
intercross and subsequent identification of cpk mutants among
the F2 mice using Cys1cpk allele-specific assay were previously
described.16,53 All F2 mice were killed 10 days after birth, their
kidneys removed and their length, weight, and volume recorded.
One of the kidneys from each animal was snap-frozen and stored in
liquid nitrogen, and the other was fixed in 10% buffered formalin
for histological evaluation. Additional mice with C57BL/6J genetic
background, either homozygous for the cpk mutation or their wild
type (unaffected) littermates from the maintenance colony, were also
killed at postnatal days 0 to 25 and their kidneys harvested similarly
to the above F2 mice. All protocols were approved by the University
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of Alabama at Birmingham (UAB) Institutional Animal Care and
Use Committee. The University of Alabama at Birmingham is fully
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International.
Gene expression profiling
We studied gene expression in mouse kidneys harvested from
the (B6-cpk/þ  CAST)F1 intercross (seven with smallest kidney
volume, eight with kidney volumes evenly distributed across
phenotypic spectrum of 461 cpk mice, and seven unaffected
controls). We also examined renal gene expression in cpk and
wild-type mice at postnatal day 0, 5, 10, 15, 20, and 25 (four
biological replicas for each phenotype and timepoint). RNA and
cDNA was prepared from whole kidneys as previously described.11
Initial gene expression analyses were performed on mice generated
in the intercross using Affymetrix GeneChip Mouse Genome 430 2.0
Arrays (Affymetrix Inc., Santa Clara, CA, USA) according to a
previously described protocol.11 All subsequent gene expression
studies that are presented in this article were performed with
TaqMan probes arranged into custom-designed low density arrays
(Applied Biosystems, Foster City, CA, USA). TaqMan assays relevant
to this article include: Mm00438094_g1 (Cd14), Mm00441243_g1
(Ccl2), and Mm00607939_s1 (Actb; a gene-encoding b-actin). Ct
values were determined with 7000 SDS RQ software (version 1.1)
and subsequently standardized using a Ct value for Actb as reference.
Actb was recommended as a suitable reference gene for this model
based on equivalence testing (a two one-sided t-test)54 using the
above Affymterix array data,11 and TaqMan Mouse Endogenous
Control Array (Applied Biosystems). The standardized Ct values
were used to determine significance of studied associations.
Immunostaining and immunoblotting
Formalin-fixed kidneys from affected cpk homozygous and un-
affected wild-type mice were paraffin-embedded and cut into
sections (3 and 5 mm). These were xylene-deparafinized, rehydrated,
and stained using rabbit polyclonal anti-human CD14 (M-305)
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
species-specific secondary antibody conjugated with biotin (Mole-
cular Probes, Eugene, OR, USA). Immunostaining was performed
after blocking tissue sections for 30 min with PBS containing
1% bovine serum albumin (Sigma, St Louis, MO, USA). Primary
antibody diluted in blocking buffer was allowed to react with
the tissues for 12-h at 41C followed by four rinses with PBS.
Immunohistochemical detection was performed with ABC complex/
HRP and DAB chromogen (DAKO) after blocking with Avidin/
Biotin blocking kit (Vector Laboratories, Burlingame, CA, USA).
Stained tissue sections were analyzed with bright field microscopy
using a Nikon E600 microscope equipped with a SPOT Insight digital
camera (Diagnostic Instruments, Sterling Heights, MI, USA). Renal
CD14-positive cell counts were quantified by histomorphometry with
Image Pro Plus v5.1 image analysis software (Media Cybernetics,
Bethesda, MD, USA). For each section and stain, six images each of
cortex and medulla from different locations were selected system-
atically to minimize selection bias. For each image, CD14-positive cells
were enumerated and the tissue area, excluding cyst and tubular
lumina, were measured. Each CD14-positive cell was visually
confirmed to assure exclusion of nonspecifically stained debris. Results
were expressed as stained cells/mm2 tissue. Statistical evaluations were
performed with SPSS 11.5 statistical software package (SPSS).
For immunoblotting, whole kidneys from three 10-day-old
cpk homozygotes with C57BL/6J genetic background, and kidneys
from three age-matched wild-type B6 mice were homogenized in
lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1%
Nonidet P40, 0.5% sodium deoxycholate, 0.7% Pepstatin and
1 tablet Complete Protein inhibitor per 50 ml (Roche Diagnostics,
Penzberg, Germany). After 10-min centrifugation at 10,000 g, the
supernatant containing solubilized membranes as well as cytosolic
material was denatured for 5 min at 951C in 2X Laemmli-reducing
buffer, and was separated by 4–12% gradient SDS-PAGE (Invitrogen,
Carlsbad, CA, USA). The gel was electrophoretically transferred
onto a Hybond-ECL membrane (Amersham, Piscataway, NJ, USA)
using a wet blotter (Invitrogen). The membrane was blocked
with 5% nonfat milk in 1X PBS/0.05% Tween-20 for 1 h at room
temperature. Subsequent washing and dilutions were done with 1X
PBS/0.05% Tween-20 at room temperature. The CD14 (M-305)
antibody and anti-b-actin antibody (Sigma) were detected after
incubation with species-specific secondary antibodies conjugated
with HRP (Molecular Probes). Activated chemiluminescence was
captured on Hyperfilm-ECL (Amersham).
The expression of CD14 protein in mIMCD-K2 cell line of SV40
transformed internal medullary collecting duct cells (gift from Erik
Schwiebert, University of Alabama at Birmingham) was validated
with reverse transcriptase PCR (RT-PCR) using intron-spanning
primers that generate 258 and 375 bp products from cDNA and
genomic DNA, respectively (50-gcctttctcggagcctatct-30 and 50-tggcttc
ggatctgagaagt-30).
Remnant human fetal RPKD and non-PKD kidneys were
collected after obtaining informed consent according to a protocol
approved by the Institutional Review Board of University of
Alabama at Birmingham (UAB). This Board also approved the
protocol for collection and analyses of remnant adult nephrecto-
mized end-stage ADPKD kidneys, control kidneys and urine that
were used in this study. The tissue processing, immunostaining, and
immunoblotting were performed in similar fashion as described
above for mouse tissues.
CD14 quantification in human serum and urine
Serum and urine from patients enrolled in the Emory ADPKD
Cohort Study were collected and analyzed according to protocols
approved by Institutional Review Boards at Emory University
and University of Alabama at Birmingham. CD14 levels were
determined using a CD14 ELISA assay (R&D Systems, Minneapolis,
MN, USA), according to the manufacturer’s protocol. Absorbances
of technical duplicates were determined using Spectra Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA). Statistical
analyses were performed with SPSS 11.5 statistical software
package (SPSS).
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